MBL HCV1

Drug Profile

MBL HCV1

Alternative Names: MBL-HCV1

Latest Information Update: 03 Mar 2016

Price : $50

At a glance

  • Originator MassBiologics
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Hepatitis C virus envelope protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatitis C
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 19 Feb 2016 MassBiologics terminates a phase II trial in Hepatitis C in USA (NCT01121185)
  • 12 Feb 2016 MassBiologics terminates phase II trial in Hepatitis C in the US (NCT01532908)
  • 14 Sep 2015 Phase-II development for Hepatitis C is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top